NanoVector Targeted Therapeutics for Late Stage Metastatic Cancer - PowerPoint PPT Presentation

NanoVector Targeted Therapeutics for Late Stage Metastatic Cancer Albert Bender, Ph.D. (919) 878-8464 abender@nanovectorinc.com

Metastatic Cancer Current Therapies Do Not Work Ovarian Cancer 5 Year Survival Rate Problems: Multidrug resistance (MDR) Maximum tolerated dose (MTD) limitation Cancer at advanced stage when diagnosed NanoVector

Solution: Targeted Nanoparticle Drug Delivery  Biologic Nanoparticle (Plant Virus)  Low cost De-risk  Stable in blood De-risk Tumor  Auto delayed release Cell  De-risk Non-immunogenic (in human food chain)  36 nm enables endocytosis  Doxorubicin cancer therapeutic (DOX)  Nanoparticle well suited to DOX  FDA approved De-risk  De-risk Broad efficacy  2 Stage Targeting :  N-cadherin receptor: highly expressed on most late stage solid tumors  Nuclear Location Signal (NLS) delivers therapeutic to site of action  Potential: Single formulation to treat De-risk multiple late stage cancers – Same Cell Surface biomarker NanoVector

N-Cadherin Targeting  N-cadherin expression is almost universal in metastatic cancers  N-cadherin is an adhesion molecule on normal cells  Space between N-cadherin-mediated cell junctions is too small for nanoparticle access  E-cadherin to N-cadherin switch occurs on cell surfaces when cancer becomes metastatic NanoVector

Formulation Overcomes MDR and MTD MTD 1: DOX Chemotherapy agent isolated from blood cells & other organs MDR: DOX Chemotherapy agent isolated from MDR MTD 2: N-cadherin secretory pathways  targeting enables higher intracellular drug 10x MTD dose + concentration longer dosing schedule MTD 3: Nuclear targeting delivers anti-cancer drug to site of action  Greater safety and efficacy NanoVector

NanoVector Lead Drug: NVI-9010  Demonstrated Efficacy in Animals:  Malignant melanoma (2011 and April 2014)  Ovarian cancer (May 2014)  Plan for Non-Invasive Companion Diagnostics  SPECT imaging of tumor with targeted Plant Virus Nanoparticle (PVN) to qualify patient for therapy  Pharmacodynamics imaging biomarker to monitor relationship of N-cadherin expression to the progression of disease NanoVector

Biologic Simplifies Manufacturing  Nanoparticles produced in plants – Low Cost De-risk  Cancer drug loaded via diffusion De-risk  Single step aqueous process for DOX loading and peptide attachment De-risk  Low cost – high yield De-risk  Manufacturing safety, lower of cost materials and disposal De-risk 37 nm 17 nm NanoVector

Capital Efficiency: cGMP Compliant Plant Partner  Leverage $21M GMP Greenhouse Facility in De-risk Research Triangle Park for plant growth  Only small isolated greenhouse required for De-risk virus transfection NanoVector

Company  Organized August 2007  7 employees  Funded by $1.8M in grants and loans  Research Augmented  NCSU Sponsored Research  NCSU Facilities use agreement  Seeking joint development opportunities:  Extend IP of existing drugs  To increase efficacy and specificity of new drugs  Joint development of new therapeutics NanoVector

Management Team Chief Executive Officer - Albert D. Bender, Ph.D. A successful serial entrepreneur who has provided the strategic vision and leadership for 4 high technology companies. Chief Scientific Officer - Bruce J. Oberhardt, Ph.D. Has led and/or participated in a number of first-of-a-kind technological developments including “CoaguChek” and founded Cardiovascular Diagnostics: a successful IPO. Board of Directors - William P. Peters, MD, PhD, MBA CEO of Adherex, a clinical stage oncology drug company, from 2003, to 2009. Formerly Dr. Peters served on the faculty at Harvard , Duke, and Wayne State University and was Associate Director, Duke Cancer Center and Director and CEO of the Karmanos Cancer Institute in Detroit NanoVector

Series A Financing  Seeking $3M equity investment to match NCI Phase IIB grant ($6M total)  Use of Funds  Complete IND-enabling studies  IND submission  Phase 1 clinical trial metastatic cancer patients  Will screen patients for target cell surface receptor NanoVector